English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/36280
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:


Small molecules targeting the vanilloid receptor complex as drug for inflammatory pain

AuthorsPlanells-Cases, Rosa; García-Martínez, Carolina; Royo, Miriam; Pérez-Payá, Enrique ; Carreño, Cristina; Albericio, Fernando; Messeguer Peypoch, Ángel ; Ferrer-Montiel, Antonio
Issue Date2003
PublisherProus Science
CitationDrugs of the Future 28(8): 787 (2003)
AbstractInflammatory pain is a condition caused by tissue injury and requires efficient drug treatment. The identification and cloning of the vanilloid receptor TRPV1 represents a significant step in the clarification of the molecular mechanisms underlying transduction of noxious chemical and thermal stimuli by peripheral nociceptors. Because of its central implication in hyperalgesia, the TRPV1 receptor has emerged as a key therapeutic target for inflammatory pain management. Modulators of the TRPV1 receptor complex are considered to be useful and selective painkillers. The challenge, however, is to develop receptor-selective drugs that preserve the physiological activity of TRPV1 receptors while correcting those contributing to pathology. Thus, normal proprioceptive and nociceptive responses that represent a safety mechanism to prevent tissue injury must be preserved.
Description28 pages, 5 figures.
Publisher version (URL)http://dx.doi.org/10.1358/dof.2003.028.08.747395
Appears in Collections:(IQAC) Artículos
Files in This Item:
File Description SizeFormat 
Panell_Rosa_et_al.pdf108,93 kBAdobe PDFThumbnail
Show full item record
Review this work

Related articles:

WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.